ArticleFrontiers in allergy2022
White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA.
Article in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Restoring the Sense of Smell: A Systematic Review and Meta-Analysis of Biologic Therapies for Chronic Rhinosinusitis with Nasal Polyps.Current allergy and asthma reports · 2025Pooled it
- Article
- National and Individual-Level Economic Burden of Local Corticosteroid Use and Concomitant Use of Multiple Local Corticosteroid Formulations-A Nationwide Cohort Study.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2026Article
- Corticosteroid Exposure in Chronic Rhinosinusitis and Global Airway Disease: Adrenal and Bone Impact.The Laryngoscope · 2026Article
- Perspectives on allergic rhinitis and related upper airway conditions: a qualitative meta-synthesis of patient and healthcare professional experiences.Irish journal of medical science · 2026Article
- Efficacy and Safety of IL-4Rα and IL-5/IL-5R Targeted Biologic Therapies in Type 2 Inflammatory Airway Diseases: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Review
- A Clinical Nomogram for Predicting Early Response to Biologics in Pediatric Allergic Asthma with Comorbid Allergic Rhinitis.Journal of asthma and allergy · 2026Article
- EUFOREA summit in Brussels 2025: inspiring the future of allergy and respiratory care.Frontiers in allergy · 2026Article
- Symptom burden in patients with chronic rhinosinusitis with nasal polyps or global airway disease prior to biologic treatment: a qualitative study of patients' experiences.Frontiers in allergy · 2025Article
- ULANC - EUFOREA workshop 2024: bringing the concept of global airways to the frontline of medical care.Frontiers in allergy · 2025Article
- Raising the bar in respiratory care by EUFOREA: report of the European Union Parliament Symposium, April 2024.Frontiers in allergy · 2025Article
- Development and validation of a Delphi consensus-based questionnaire for the multidisciplinary management of type 2 inflammation-related diseases.Frontiers in allergy · 2025Article
- The future of allergic rhinitis management: A partnership between healthcare professionals and patients.The World Allergy Organization journal · 2024Article
- Multidisciplinary management of type 2 inflammation diseases using a screening tool.Frontiers in allergy · 2024Article
- A clinical study on the relationship between chronic rhinosinusitis and bronchial asthma.Frontiers in medicine · 2024Article
- Editorial: 2022 in review: rhinology.Frontiers in allergy · 2024Article
- EUFOREA meeting on defining disease states in allergic rhinitis: towards a unified language in AR.Frontiers in allergy · 2024Article
- Nasal polyp syndrome: a patient-centred term for CRSwNP by EUFOREA.Frontiers in allergy · 2024Article
- European biologic training course for type 2 inflammation by EUFOREA in 2024: key facts and lessons learned.Frontiers in allergy · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 10 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, little is known about the similarities and differences in experiences and perspectives of the current management of patients with comorbid Type 2 inflammatory diseases. Aims: To improve insight into the common and organ-specific needs of patients with Type 2 inflammation and comorbidities, allowing the formulation of recommendations to better address these needs in the future. Methodology: This qualitative study was conducted between July 2021 and December 2021 using semi-structured face-to-face or telephone interviews with patients suffering from year-long severe chronic Type 2 inflammation and at least one co-morbid inflammatory condition. Seven participating academic centers in Europe interviewed asthma (Copenhagen and Leuven), CRSwNP (London, Amsterdam and Crete) and/or AD (Oldenburg and Zurich) patients on patient characteristics, disease severity, shortcomings of current care pathways and suggestions for improvement of care. Transcripts were analyzed using an inductive thematic analysis approach. Results: Eighty-one patients with severe Type 2 inflammation and comorbidities were interviewed. Similar needs were recognized by patients with Type 2 inflammation, with both a lack of coordination in care and a lack of a real cure reported as being most frustrating. However, several needs are specific to asthma, CRSwNP and AD. Suggestions for improvement of care were generic across diseases, such as the implementation of a multidisciplinary approach, the improved facilitation of access to better treatments, the increase of general awareness on disease burden, and better educational programs for healthcare providers and patients. Of note, patients with CRSwNP also stated the need for alternatives to sinus surgery, whereas patients with asthma requested better medical care to prevent exacerbations and patients with AD would warmly welcome the reimbursement of emollients. Conclusion: Patients with asthma, CRSwNP and AD have shared unmet needs that need to be addressed by physicians, the academic community and health policy makers. This survey provides unique recommendations made by patients for the implementation of better care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.